Synonyms: Yonsa® | Zytiga®
abiraterone acetate is an approved drug (EMA & FDA (2011))
Compound class:
Synthetic organic
Comment: Abiraterone acetate is an ester prodrug of the steroidal drug abiraterone, which acts as an androgen synthesis inhibitor by inhibiting steroid 17alpha-monooxygenase.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Abiraterone acetate is used to treat refractory prostate cancer in combination with prednisone or prednisolone. In May 2018, the US FDA approved a novel, ultramicrosized formulation of abiraterone acetate (Yonsa®) for the treatment of metastatic castration-resistant prostate cancer, that is to be used in combination with methylprednisolone. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |